Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 20/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.47 |
| ▸ | SLC2A9 | Q9NRM0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10228288 | 0.87 | SLC22A12 (0.53) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL10226541 | 0.86 | SLC22A12 (0.52) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL10176891 | 0.85 | SLC22A12 (0.49) | SLC22A12CYP2C9CYP1A2 | |
| SCHEMBL10228700 | 0.85 | SLC22A12 (0.51) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL10177145 | 0.84 | SLC22A12 (0.79) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL1924767 | 0.82 | SLC22A12 (0.76) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL12056208 | 0.82 | SLC22A12 (0.66) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL10176892 | 0.82 | SLC22A12 (0.46) | SLC22A12CYP2C9CYP1A2 | |
| SCHEMBL1300156 | 0.81 | SLC22A12 (1.00) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL13444888 | 0.81 | SLC22A12 (0.78) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546437-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546437-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120164222-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120164222-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120164222-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.